ATHIRA PHARMA INC. - COMMON STOCK
0.7096
14-November-24 09:57:06
15 minutes delayed
Stocks
-0.0204
-2.79%
Today's range
0.6928 - 0.7472
ISIN
N/A
Source
NASDAQ
-
Athira Pharma Presents Preclinical Data at the Alzheimer's Association International Conference 2022
02 Aug 2022 14:30:00 By Nasdaq GlobeNewswire
-
25 Jul 2022 06:00:00 By Nasdaq GlobeNewswire
-
22 Jun 2022 06:00:01 By Nasdaq GlobeNewswire
-
07 Jun 2022 06:00:00 By Nasdaq GlobeNewswire
-
Shareholders Approve the Election of All Three Athira Director Nominees at 2022 Annual Meeting
19 May 2022 11:06:13 By Nasdaq GlobeNewswire
-
Athira Issues Statement in Response to Richard A. Kayne’s Suspension of His Proxy Contest
16 May 2022 15:49:31 By Nasdaq GlobeNewswire
-
Athira Pharma Presents Preclinical Data at the 2022 Peripheral Nerve Society (PNS) Annual Meeting
16 May 2022 06:00:01 By Nasdaq GlobeNewswire
-
12 May 2022 15:05:02 By Nasdaq GlobeNewswire
-
Athira Urges Shareholders to Support its Director Nominees at May 19 Annual Meeting
11 May 2022 15:15:00 By Nasdaq GlobeNewswire
-
09 May 2022 06:00:02 By Nasdaq GlobeNewswire
-
05 May 2022 11:03:56 By Nasdaq GlobeNewswire
-
05 May 2022 07:00:03 By Nasdaq GlobeNewswire
-
04 May 2022 17:46:09 By Nasdaq GlobeNewswire
-
26 Apr 2022 07:00:03 By Nasdaq GlobeNewswire
-
20 Apr 2022 08:02:06 By Nasdaq GlobeNewswire
-
Athira Files Definitive Proxy Statement and Mails Letter to Shareholders
05 Apr 2022 15:04:20 By Nasdaq GlobeNewswire
-
04 Apr 2022 06:00:01 By Nasdaq GlobeNewswire
-
Athira Pharma Highlights Strong Execution of Strategy and Positioning for the Future
30 Mar 2022 11:12:04 By Nasdaq GlobeNewswire
-
Athira Pharma Reports Full Year 2021 Financial Results and Provides Clinical Update
24 Mar 2022 15:05:01 By Nasdaq GlobeNewswire
-
Athira Pharma Announces Appointment of Dr. Michael A. Panzara to its Board of Directors
21 Mar 2022 06:05:00 By Nasdaq GlobeNewswire